GEORGE MACKEL: Open Payments
NPI 1891082376 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,667 in 72 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $91 · 2025 $1,667
Food & beverage: $1,667
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $430 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $200 |
| Neurocrine BioSciences, Inc. | 2 | $189 |
| E.R. Squibb & Sons, L.L.C. | 7 | $170 |
| Janssen Pharmaceuticals, Inc | 7 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $167 |
| Teva Pharmaceuticals USA, Inc. | 5 | $108 |
| Lundbeck LLC | 4 | $99 |
| Alkermes, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, COBENFY, INVEGA SUSTENNA, FANAPT, REXULTI, AUSTEDO XR.
Industry payments across HI — which companies pay providers there.
